No abstract

The Daya Bay experiment has observed correlations between reactor core fuel evolution and changes in the reactor antineutrino flux and energy spectrum. Four antineutrino detectors in two experimental halls were used to identify 2.2 million inverse beta decays (IBDs) over 1230 days spanning multiple fuel cycles for each of six 2.9 GW$_{\textrm{th}}$ reactor cores at the Daya Bay and Ling Ao nuclear power plants. Using detector data spanning effective $^{239}$Pu fission fractions, $F_{239}$, from 0.25 to 0.35, Daya Bay measures an average IBD yield, $\bar{\sigma}_f$, of $(5.90 \pm 0.13) \times 10^{-43}$ cm$^2$/fission and a fuel-dependent variation in the IBD yield, $d\sigma_f/dF_{239}$, of $(-1.86 \pm 0.18) \times 10^{-43}$ cm$^2$/fission. This observation rejects the hypothesis of a constant antineutrino flux as a function of the $^{239}$Pu fission fraction at 10 standard deviations. The variation in IBD yield was found to be energy-dependent, rejecting the hypothesis of a constant antineutrino energy spectrum at 5.1 standard deviations. While measurements of the evolution in the IBD spectrum show general agreement with predictions from recent reactor models, the measured evolution in total IBD yield disagrees with recent predictions at 3.1$\sigma$. This discrepancy indicates that an overall deficit in measured flux with respect to predictions does not result from equal fractional deficits from the primary fission isotopes $^{235}$U, $^{239}$Pu, $^{238}$U, and $^{241}$Pu. Based on measured IBD yield variations, yields of $(6.17 \pm 0.17)$ and $(4.27 \pm 0.26) \times 10^{-43}$ cm$^2$/fission have been determined for the two dominant fission parent isotopes $^{235}$U and $^{239}$Pu. A 7.8% discrepancy between the observed and predicted $^{235}$U yield suggests that this isotope may be the primary contributor to the reactor antineutrino anomaly.Comment: 7 pages, 5 figure

This work reports a precise measurement of the reactor antineutrino flux using 2.2 million inverse beta decay (IBD) events collected with the Daya Bay near detectors in 1230 days. The dominant uncertainty on the neutron detection efficiency is reduced by 56% with respect to the previous measurement through a comprehensive neutron calibration and detailed data and simulation analysis. The new average IBD yield is determined to be ð5.91 AE 0.09Þ × 10 −43 cm 2 =fission with total uncertainty improved by 29%. The corresponding mean fission fractions from the four main fission isotopes 235 U, 238 U, 239 Pu, and 241 Pu are 0.564, 0.076, 0.304, and 0.056, respectively. The ratio of measured to predicted antineutrino yield is found to be 0.952 AE 0.014 AE 0.023 (1.001 AE 0.015 AE 0.027) for the Huber-Mueller (ILL-Vogel) model, where the first and second uncertainty are experimental and theoretical model uncertainty, respectively. This measurement confirms the discrepancy between the world average of reactor antineutrino flux and the Huber-Mueller model.

The Daya Bay Experiment consists of eight identically designed detectors located in three underground experimental halls named as EH1, EH2, EH3, with 250, 265 and 860 meters of water equivalent vertical overburden, respectively. Cosmic muon events have been recorded over a two-year period. The underground muon rate is observed to be positively correlated with the effective atmospheric temperature and to follow a seasonal modulation pattern. The correlation coefficient α, describing how a variation in the muon rate relates to a variation in the effective atmospheric temperature, is found to be α EH1 = 0.362 ± 0.031, α EH2 = 0.433 ± 0.038 and α EH3 = 0.641 ± 0.057 for each experimental hall.

High-mobility group box 1 protein (HMGB1), a ubiquitous nuclear DNAbinding protein, functions as a potent proinflammatory factor. In this study, we evaluated the effects of HMGB1 inhibition on murine lupus using the lupusprone model. We treated male BXSB mice with neutralizing anti-HMGB1 monoclonal antibody (HMGB1 mAb) from age 16 weeks to 26 weeks. The control group received the same amount of control IgG. Lupus-prone male BXSB mice treated with HMGB1mAb showed attenuated proteinuria, glomerulonephritis, circulating anti-dsDNA and immune complex deposition. Levels of serum IL-1b, IL-6, IL-17 and IL-18 were also significantly decreased by administration of HMGB1mAb in lupus-prone BXSB mice. HMGB1mAb treatment also decreased the caspase-1 activity in the kidneys of BXSB mice and reduced the mouse mortality. Our study supports that HMGB1 inhibition alleviates lupus-like disease in BXSB mice and might be a potential treatment option for human SLE.